Aim: In Duchenne muscular dystrophy (DMD) populations, a higher prevalence of epilepsy has been found compared with control groups. We hypothesized that epilepsy/seizures causes loss of dystrophin in the brain. Our aim was to localize dystrophin in cerebellum and hippocampus and to develop a reliable method for quantification of dystrophin. 
Introduction
Duchenne muscular dystrophy (DMD) is a X chromosome-linked recessive neuromuscular disorder affecting approximately 1 in every 3500 alive male newborns. The disorder is caused by a mutation in the dystrophin gene, which results in progressive muscle degeneration caused by the replacement of muscle tissue with fat and fibrous tissue occurring not only in skeletal muscles, but also in heart, respiratory muscles and in the central nervous system (CNS). Degeneration in muscles causes significant motor development disorder and muscle weakness, starting in the legs and pelvis. In the brain, degeneration causes cognitive and behavioural disabilities.
Dystrophin is a cytoplasmic protein linking cytoskeletal actin filaments to membrane proteins that is abundantly expressed in muscular tissue, but it can also be found in the retina, kidney and CNS. Therefore, some DMD patients have less dystrophin in the brain, depending on the location of the mutation.
Dystrophin is involved in the clustering of different ion channels and postsynaptic membrane receptors in the brain, for example the clustering of aquaporin channels, kainate-type glutamate receptors and particularly GABA A receptors, which suggests that a loss of its function may be the cause of cognitive deficits in DMD patients.
Dystrophin exists of a few isoforms, these include Dp427, Dp 71 and Dp140. In the brain Dp427 is expressed in hippocampal neurons, cortical pyramidal cells, cerebellar Purkinje cells and Dp427 has been found to colocalize with γ-aminobutyric acid type A (GABA A ) receptors and seems to play an important role in the clustering and stabilization/ anchoring of GABA A receptors. Dp71 in the brain is found in neurons and glia, most notably in perivascular astrocytes and cerebellar Bergman glia. Expressed at the specialized endfeet processes of perivascular astrocytes, Dp71 is suggested to play a role in maintaining the function of the blood brain barrier (BBB), in which aquaporin 4 plays a role and Dp71 appears to be involved in the clustering of potassium channel Kir 4.1 that maintains potassium homestasis in astrocytes.
The prevalence of epilepsy is higher in DMD population compared in control population; Goodwin et al. reported a prevalence of 3,1%, Etemadifar and Molaei 12,3% and Pane et al. 6 ,3% in DMD population compared with control populations of 0,4%-0,5%, 0,5%-1% and 0,5%-1% respectively. These reports raised the question whether a reduced expression of dystrophin is linked with increased seizure susceptibility.
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The question remains if dystrophin alterations are cause or consequence of epileptogenesis/seizures, because the studies are based on patients who have been suffering from epilepsy for years and on animal models of epilepsy/seizures. Therefore, the aim of this study was to determine this question. We hypothized that the presence of seizures causes loss/decrease of dystrophin and that the decrease of dystrophin is a consequence of epileptogenesis in a rodent model for temporal lobe epilepsy. In this hypothesis, the aim was to localize dystrophin in the cerebellum and hippocampus and to produce a reliable method to quantify the dystrophin.
Material and methods
In the amygdala kindling model, a rodent model for temporal lobe epilepsy, 
Pilot study 1
The cerebellar tissue was split into two even groups to perform two different staining Samples were counterstained with Hoechst diluted 1:500 for 30 minutes after washing.
Samples were washed and mounted on gelatin coated slides with 80% glycerol in TBS and closed with nail polish.
Pilot study 2
Hippocampal tissue of two amygdala kindled rats were stained anti-NeuN, anti-dystrophin and Hoechst. The samples were washed and blocked with blocking buffer for 60 minutes.
After blocking, incubation with primary anti-dystrophin was performed overnight at 4 °C with a 1:500 dilution in blocking buffer. These samples were washed and incubated with 
Quantification of immunohistochemical signal
After the stainings, pictures were taken using the software micromanager with fluorescent 
Statistical analysis
In order to measure the reliability of this self-constructed quantification method, intraobserver correlation was calculated using Pearson's correlation and intra-class coefficient 
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the Purkinje cell was measured. Subsequently, the substraction of these two values (inside and outside delineation of dystrophin surrounding the Purkinje cell) was used as a value for dystrophin expression around that specific Purkinje cell. Several days later the same procedure was performed in a different order. These two values were used to calculate the intra-observer correlation (Pearson correlation and intra-class correlation) of the mean grey value and the intensity density.
Results

Immunofluorescence
In the cerebellum, dystrophin was localized around the Purkinje somatic and dendritic membranes. Here, the same can be seen. When the dystrophin and calbindin pictures were merged, dystrophin is localized around the Purkinje cells. In some Purkinje cells yellow was seen to suggest colocalization, while some did not (figure 1). Negative control of primary dystrophin antibody showed no immunoreactivity in Purkinje neurons.
In the cerebellum sections stained with GFAP, an abundant amount of astrocytes can be seen and dystrophin seems to be expressed at the same places as GFAP (figure 2). When GFAP was merged with dystrophin, the astrocytes were yellow, which suggests, again, a profound colocalization of dystrophin and astrocytes in the cerebellum ( figure 2A, C, F ).
This is a new finding, as other authors failed to demonstrate dystrophin in other structures than Purkinje cells. Interestingly, in both the dystrophin and GFAP staining, dystrophin and glia seem to surround a round structure ( figure 2B, D) . When both pictures were merged, these round structures were surrounded by yellow ellipses ( figure 2F ).
In the hippocampus, GFAP labelling also showed an abundant amount of astrocytes.
When comparing the dystrophin and GFAP pictures, it seems that the structures seen on both pictures are in a similar locations ( figure 3A , B, C, D). Indeed, when the pictures were merged, the astrocytes are yellow. So it would seem that dystrophin and astrocytes also colocalize in the hippocampus ( figure 3E, F ).
With NeuN labelling, which is standard used for hippocampal neuron stainings, it was difficult to distinguish single cells due to a high cell density. In the dystrophin pictures, dystrophin surrounds round/oval structures in which the cells labelled with NeuN seem to fit in. However, no dystrophin was seen around neuronal hippocampal cells, which suggests that there is no colocalization of dystrophin and neuronal cells (figure 4E, F). Table 1 . Pearson correlation and ICC of the mean grey value and intensity density **. Correlation is significant at the 0,01 level (2-tailed).
Statistical analysis
Pearson correlation ICC
Mean grey value 1,000** 1,000
Intensity density 0,986** 0,984
Because it was initially thought that no signal was present of neuronal cells in calbindin labelled hippocampal tissue, only dystrophin around the glia cells and around the Purkinje cell were quantified. However, for glia cells, the quantification method was not compatible, because the axons and dendrites were thin and irregular, so manually delineation was not possible. At the end only dystrophin around Purkinje cells in the cerebellum were quantified.
Pearson correlation and ICC of the mean grey value were both 1,000, which means a significant correlation (P<0,0001) ( around the Purkinje cell, might consist of the isoforms Dp427 or Dp71, which could not be distinguished by the dystrophin antibody used in this study. Another problem is that this antibody binds to all isoforms since it is directed against the C-terminal of the dystrophin protein, thereby also staining Dp140. Since not much is known about Dp140, it cannot be excluded that Dp140 might be present in the stainings here as well. Further research is necessary to answer these questions.
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For a more specific staining, two antibodies against dystrophin could be used: one antibody directed against the N-terminal of the protein, which binds to all isoforms and one antibody directed against the C-terminal, which is specific for the full-length Dp427 isoform. The difference of dystrophin stained by the two antibodies, is thus Dp140 or Dp71.
For stainings against only one isoform, it might be possible to use existing monoclonal antibodies against these isoforms. In glia cells, a colocalization between GFAP-positive glia cells and dystrophin is suggested ( figure 2 To investigate this possibility, triple staining could be done with differently generated primary antibodies. If it appears to be Bergman glia, for sure that isoform is Dp71. However, when it appears to be Purkinje cells where the dystrophin is located, no conclusion can be made as both Dp427 and Dp71 are expressed in neurons. If this is the case, staining against the N-terminal and the C-terminal of the protein could be used.
Dystrophin in the hippocampus
With the NeuN labelling, the neuronal cells were not distinguishable. The cell density seems to be very high and the cells blurry. This could be caused by the use of a widefield fluorescence microscope, BX51, so more out-of-focus light is present. Also, no colocalization could be found between NeuN labelled neurons and dystrophin (figure 4). NeuN is a specific protein expressed in post-mitotic neurons and primarily stains the neuronal nucleus, but also cytoplasm and dendrites. However, dystrophin is found at the celmembrane and thus might still possibly colocalize with hippocampal neuronal cells at the membrane, which is not visible with the used staining.
In glia cells, a colocalization between GFAP-positive glia cells and dystrophin is suggested (figure 3), which is in contrast to previous literature. Here, it is also unknown which isotype is expressed in these cells.
Quantification of dystrophin around Purkinje cells
The intra-observer correlation of both the mean grey value and intensity density were very high for as well the Pearson correlation (r=1,000, P<0,0001 for mean grey value and r=0,986, P<0,0001 for the intensity density) as for the ICC (r=1,000, P<0,0001 for mean grey value and r=0,984, P<0,0001 for the intensity density). A r-value close to 1 suggest a perfect correlation and thus suggests that the method seems reliable. An interobserver correlation calculation might be useful in the near future. It is expected that the interobserver correlation will be high, if the other person is consistent in his/her method.
As was mentioned before, delineation of glia cells in the cerebellum and hippocampus was not possible manually, because the glia cells with the dystrophin have many thin dendrites, which could not be delineated accurately. Another method is necessary. A possible solution is to count the dystrophin positive glia cells and express these cells in a percentage for comparison between the experimental groups.
Conclusion
Dystrophin is ubiquitously expressed in the cerebellum and hippocampus, but the exact distribution of the dystrophin isoforms in these areas are not clear yet. We, however, demonstrate here to have developed an adequate protocol for dystrophin staining of the cerebellum and hippocampus. Also, we have developed a reliable manual quantification method of dystrophin around the cerebellar Purkinje cells. The more challenging part seems to be the quantification of dystrophin in cerebellar and hippocampal glia cells and hippocampal neurons. Future studies should therefore be aimed at tackling such problems.
